# Role of FXI in Thrombohemorrhagic Complications > **NIH NIH F31** · OREGON HEALTH & SCIENCE UNIVERSITY · 2020 · $12,836 ## Abstract Project Summary Sepsis is a prevalent cause of hospital mortality. Terminal complications of sepsis include hemorrhage and multi-organ failure due to consumption of platelets and coagulation factors into clots within microcirculation, condition termed disseminated intravascular coagulation (DIC). Platelets and coagulation factors play a vital role in hemostatic plug formation to staunch blood loss upon blood vessel barrier breach. A similar process can also lead to pathological thrombus formation and consequential thrombotic complications and potentially DIC. There is a pressing need for a better (patho)mechanistic understanding of thrombosis versus hemostasis, which could help guide therapeutic interventions to prevent DIC while preserving hemostasis in septic patients. Thrombosis and hemostasis appear to separate mechanistically upstream of coagulation factor XI (FXI), as FXI and coagulation factor IX (FIX) deficiency cause mild and severe hemophilia, respectively, but coagulation factor XII (FXII) deficiency is asymptomatic. FXI-deficient humans are largely protected from deep vein thrombosis and ischemic stroke. Furthermore, inhibition of FXI activation by activated FXII (FXIIa) improves survival in mice with peritoneal sepsis or listeriosis. Thus, FXI inhibition could help prevent the thrombotic complications of sepsis. My preliminary data show that FXI promotes platelet activation and consumption in the bloodstream distal to a thrombus formation. We have previously shown that inhibiting FXI activation by FXIIa attenuated inflammation while improving survival of mice with fecal peritonitis. These findings suggest that FXIa is a multifunctional enzyme involved in different aspects coagulation and cellular response pertinent to sepsis progression. I hypothesize that FXI contributes to DIC by amplifying thrombin generation and directly affecting platelet interactions and endothelial barrier functions under shear. The goal of the proposed training plan is to delineate the mechanisms by which FXI contributes to sepsis- induced thrombotic complications. Specific Aim 1 will determine the role of FXI in platelet consumption under shear flow. These studies will determine whether the presence of bacterial wall components promotes thrombin generation and subsequent platelet consumption in the bloodstream in a FXI-dependent manner. Specific Aim 2 will determine the role of FXI in endothelial barrier dysfunction. I will determine whether FXI activity contributes directly or indirectly to endothelial barrier leak and subendothelial compartment exposure to the bloodstream. Collectively, my research will help define the role of FXI in sepsis and may lead to target identification for new therapies to improve patient outcomes. The objective of this fellowship is to attain a highly integrative training that would allow me to reach the competency I need to realize the research aims outlined in this proposal and pursue my future goal of becoming an effective phy... ## Key facts - **NIH application ID:** 9843687 - **Project number:** 5F31HL136230-04 - **Recipient organization:** OREGON HEALTH & SCIENCE UNIVERSITY - **Principal Investigator:** Jevgenia Zilberman-Rudenko - **Activity code:** F31 (R01, R21, SBIR, etc.) - **Funding institute:** NIH - **Fiscal year:** 2020 - **Award amount:** $12,836 - **Award type:** 5 - **Project period:** 2017-01-03 → 2020-03-20 ## Primary source NIH RePORTER: https://reporter.nih.gov/project-details/9843687 ## Citation > US National Institutes of Health, RePORTER application 9843687, Role of FXI in Thrombohemorrhagic Complications (5F31HL136230-04). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/9843687. Licensed CC0. --- *[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*